ClearOne shareholders back issuance of 12,500,000 shares for Cortigent merger by written consent
CLRO•Merger consideration, financing and board changes
The actions authorized issuance of 12,500,000 common shares to Vivani as merger consideration, a transaction expected to shift control under Nasdaq rules.
They also adopted a 2026 Omnibus Incentive Plan with a 2,500,000-share reserve for equity awards.
Transaction terms also contemplate up to 855,000 advisor shares, a $10 million–$15 million unit financing, a reconstituted five-member board, and rebranding to Cortigent Holdings.
Shareholders approve key steps for Cortigent merger
ClearOne board actions, backed by majority written consent, cleared key steps for a Cortigent acquisition via a July 1, 2026 merger agreement.
Written consent dated Aug. 3, 2026 from First Finance Ltd. covered 1,641,162 shares, or 61.3% of 2,675,412 outstanding shares.
